Corbus Pharmaceuticals Announces Patent Issuance Covering Use of Lenabasum for the Treatment of Fibrotic Diseases Providing Exclusivity to 2034
October 03, 2018 09:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Company’s vision is to become the leader in the treatment of inflammatory and fibrotic diseases by targeting the endocannabinoid systemIntellectual property around pipeline targeting endocannabinoid...
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in October
September 26, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
– Cantor Global Healthcare Conference presentation with live audio webcast on Monday, October 1st at 2:55 PM ET – – Leerink Partners Roundtable Series: Rare Disease & Oncology fireside chat...
Corbus Pharmaceuticals Reports 2018 Second Quarter Financial Results and Provides Business Update
August 08, 2018 09:00 ET | Corbus Pharmaceuticals Holdings, Inc.
Lenabasum has reached Phase 3 clinical stage in two orphan autoimmune indications: systemic sclerosis and dermatomyositis, affecting up to 200,000 patients in the USA, EU and JapanRecent long-term...